Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-FLUOXETINE | 10MG | CAPSULE | Resolved | 2024-12-11 | 2025-03-14 | 245456 |
| APO-FLUOXETINE | 20MG | CAPSULE | Resolved | 2022-09-16 | 2022-09-30 | 169510 |
| APO-FLUOXETINE | 20MG | SOLUTION | Resolved | 2023-04-27 | 2023-05-06 | 190850 |
| APO-FLUOXETINE | 20MG | CAPSULE | Resolved | 2024-02-26 | 2024-03-01 | 220650 |
| APO-FLUOXETINE | 20MG | CAPSULE | Resolved | 2022-11-04 | 2023-03-02 | 173815 |
| APO-FLUTICASONE HFA | 125MCG | METERED-DOSE AEROSOL | Resolved | 2023-10-27 | 2023-11-06 | 208406 |
| APO-FLUTICASONE HFA | 125MCG | METERED-DOSE AEROSOL | Resolved | 2024-11-14 | 2024-12-20 | 243089 |
| APO-FLUTICASONE HFA | 50MCG | AEROSOL, METERED DOSE | Actual shortage | 2026-01-16 | 2026-01-16 | 276268 |
| APO-FLUTICASONE HFA | 125MCG | METERED-DOSE AEROSOL | Resolved | 2023-02-23 | 2023-03-02 | 185486 |
| APO-FLUTICASONE HFA | 125MCG | METERED-DOSE AEROSOL | Resolved | 2024-07-12 | 2024-08-09 | 232835 |
| APO-FLUVOXAMINE | 50MG | TABLET | Resolved | 2023-04-06 | 2023-07-27 | 188940 |
| APO-FLUVOXAMINE | 50MG | TABLET | Resolved | 2022-09-01 | 2022-10-07 | 168367 |
| APO-FLUVOXAMINE | 100MG | TABLET | Resolved | 2024-04-05 | 2024-05-17 | 224592 |
| APO-FLUVOXAMINE | 100MG | TABLET | Resolved | 2023-10-20 | 2024-01-19 | 207710 |
| APO-FLUVOXAMINE | 50MG | TABLET | Resolved | 2022-12-23 | 2023-02-17 | 179453 |
| APO-FLUVOXAMINE TABLETS | 50MG | TABLET | Resolved | 2020-10-14 | 2020-11-02 | 126280 |
| APO-FLUVOXAMINE TABLETS | 100MG | TABLET | Resolved | 2021-11-01 | 2021-11-29 | 148587 |
| APO-FLUVOXAMINE TABLETS | 50MG | TABLET | Resolved | 2022-02-11 | 2022-02-22 | 154759 |
| APO-FLUVOXAMINE TABLETS | 100MG | TABLET | Resolved | 2022-02-11 | 2022-02-22 | 154756 |
| APO-FLUVOXAMINE TABLETS | 50MG | TABLET | Resolved | 2021-10-15 | 2021-11-29 | 147292 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |